
|Videos|December 13, 2022
A Model That Is Built to “Win”
Cutting the amount of Monthly Enhanced Oncology Services payments and limiting qualifying tumor types will curtail revenue to practices. But after the financial results in the Oncology Care Model, that's by design.
Advertisement
Episodes in this series

Panelists discuss the financial fallout from the design of the Enhancing Oncology Model (EOM), which responds to the reports that found the Oncology Care Model succeeded in delivering better care but didn't save enough Medicare enough money in its early years, at least not in practices that were less proficient in operating the model. Kashyap Patel, MD, suggests other payment model programs that could work in tandem with the EOM.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Boston Panel Confronts Access and Coordination Gaps in Obesity Care
5






